-

Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™

Clinical Stage Biotech Company Partners with Premier Compounding Pharmacy to Provide Doses for IRB Cleared Phase I/II Clinical Trial

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) spin-off Res Nova Bio announced today a collaboration with Cure Stat Rx, a premiere compounding Pharmacy in the manufacture of initiate doses of FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.

The Company previously announced Institutional Review Board clearance to initiate the clinical trial. As part of the collaboration, Ramesh Chigurupati, President of Cure Stat Rx has joined the Advisory Board of Res Nova.

“I am honored to partner with Chigurupati and the team at Cure Stat Rx who have second-to-none expertise in compounding and drug formulation across a range of therapeutic indications,” said Famela Ramos, President, and CEO of Res Nova Bio. “Based on our preclinical and pilot clinical data, we are confident that our proposed Phase I/II trial will support the use of FloraStilbene as an immune enhancer in general and specifically a stimulator of natural killer cell activity in advanced cancer patients.”

“I have worked with Chigurupati for many years in delivering personalized medicine to patients,” said Dr. James Veltmeyer, Chief Medical Officer of Res Nova. “Having seen first-hand the potent therapeutic effects of the Res Nova immunotherapy product ValloVax, I look forward to working with Cure Stat Rx to translate FloraStilbene into the clinical domain.”

Cure Stat Rx is an accredited compounding pharmacy specializing in cancer treatments. Cure Stat Rx clinical and compounding staff is knowledgeable and well trained in immuno-oncology.

“Despite significant advances in cancer immunotherapy, many approaches do not induce responses because patients have low immune responses to begin with. By leveraging the significant body of work developed by TSOI in the area of pterostilbene and immuno-oncology, it is exciting to watch how rapidly Famela Ramos and her team are moving towards treating patients with this first in class approach,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International and Chairman of Res Nova Bio.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

Contacts

Timothy G. Dixon
ir@tsoimail.com

Therapeutic Solutions International, Inc.

OTC Pink:TSOI

Release Versions

Contacts

Timothy G. Dixon
ir@tsoimail.com

More News From Therapeutic Solutions International, Inc.

Therapeutic Solutions International to Voluntarily Delist

ELK CITY, Idaho--(BUSINESS WIRE)--Timothy G Dixon, Therapeutic Solutions International CEO issued the following statement: Therapeutic Solutions International, Inc. (TSOI) announced today their intent to delist and “go dark” from the public markets. Please take Notice: on April 22, 2025, the Board of Directors, with the consent of a majority of eligible voting shareholders of the Company, approved a voluntary withdrawal of the class of securities from listing and registration on the Exchange an...

Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Stimulation of Mesenchymal Stem Cell Therapeutics Activities by Regulatory T Cells.” The issued patent claims include: “A method of inhibiting lung inflammation comprising: a) identifying a subject suffering from lung inflammation; b) administering a population of T regula...

Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company. Therapeutic Solutions International pre-spin-off company, Campbell Neurosciences, Inc., announced today appointment of seasoned public company veteran Mr. Raymond Oliver as Chairman of its Board of Directors. This move is part of a larger strategy the suicide prevention company is impl...
Back to Newsroom